{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:59:29Z","timestamp":1792799969712,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Fibromyalgia (FM) subjects are treated with antidepressant agents; in most cases, these drugs lose efficacy or have adverse effects. Ketamine is an anesthetic drug used in FM in some studies. This article aims to systematically review the safety and efficacy of ketamine in fibromyalgia (FM) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We systematically searched articles on FM and ketamine published at Pubmed from 1966 to 2021. This study was registered at PROSPERO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were only 6 articles published in this field, with a total of 115 patients. The female sex was predominant (88 to 100%). The age varied from 23 to 53 years old. Disease duration ranged from 1 month to 28 years. The dosage of ketamine changed from 0.1\u00a0mg\/kg-0.3-0.5\u00a0mg\/kg in intravenous infusion (4\/5) and subcutaneous application (1\/5). Regarding outcomes, the Visual analog scale (VAS) before ketamine was from 59 to 100\u00a0mm and after treatment from 2 to 95\u00a0mm. Most short-term studies had a good response. Only the study with 8 weeks of follow-up did not observe a good response. Side effects were common; all appeared during the infusion and disappeared after a few minutes of the ketamine injection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present study demonstrates the effectiveness and safety of ketamine in FM patients in the short term. Although, more studies, including long-term follow-up studies, are still needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-024-00393-9","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T12:52:39Z","timestamp":1722257559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ketamine in fibromyalgia: a systematic review"],"prefix":"10.1186","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7957-0844","authenticated-orcid":false,"given":"Joz\u00e9lio Freire","family":"de Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Pond\u00e9","family":"de Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"393_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41584-020-00506-w","volume":"16","author":"P Sarzi-Puttini","year":"2020","unstructured":"Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16:645\u201360.","journal-title":"Nat Rev Rheumatol"},{"key":"393_CR2","doi-asserted-by":"crossref","unstructured":"Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. Taylor & Francis; 2015:1347\u201368.","DOI":"10.1517\/14656566.2015.1047343"},{"key":"393_CR3","first-page":"CD010585","volume":"2","author":"J Thorpe","year":"2018","unstructured":"Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev. 2018;2:CD010585.","journal-title":"Cochrane Database Syst Rev"},{"key":"393_CR4","first-page":"297","volume":"20","author":"FA Rathore","year":"2020","unstructured":"Rathore FA, Afridi A. Is combination pharmacotherapy effective for the management of fibromyalgia in adults? - a cochrane review summary with commentary. J Musculoskelet Neuronal Interact. 2020;20:297\u2013300.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"393_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pain.2009.08.007","volume":"149","author":"RA Moore","year":"2010","unstructured":"Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, Bell RF, Kalso E, Rowbotham MC, ACTINPAIN writing group of the IASP Special Interest Group (SIG) on Systematic Reviews in Pain Relief. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain. 2010;149:173\u20136.","journal-title":"Pain"},{"key":"393_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcp.12094","volume":"77","author":"M Niesters","year":"2014","unstructured":"Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77:357\u201367.","journal-title":"Br J Clin Pharmacol"},{"key":"393_CR7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/AAP.0000000000000756","volume":"43","author":"ES Schwenk","year":"2018","unstructured":"Schwenk ES, Dayan AC, Rangavajjula A, Torjman MC, Hernandez MG, Lauritsen CG, Silberstein SD, Young W, Viscusi ER. Ketamine for refractory headache: a retrospective analysis. Reg Anesth Pain Med. 2018;43:875\u20139.","journal-title":"Reg Anesth Pain Med"},{"key":"393_CR8","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"393_CR9","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovi\u0107 J, Schulz KF, Weeks L, Sterne JA. The Cochrane collaboration\u2019s tool for assessing the risk of bias in randomized trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"393_CR10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.ejpain.2011.03.008","volume":"15","author":"I Noppers","year":"2011","unstructured":"Noppers I, Niesters M, Swartjes M, Bauer M, Aarts L, Geleijnse N, Mooren R, Dahan A, Sarton E. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double-blind, active placebo-controlled trial. Eur J Pain. 2011;15:942\u20139.","journal-title":"Eur J Pain"},{"key":"393_CR11","first-page":"151","volume":"6","author":"A Muller","year":"2005","unstructured":"Muller A, Rempp C, Kopferschmitt J, Haeringer M-T, Brandt C, Meyer P, Kuntz J-L, Sibilia J, Warter J-M. Effets De La k\u00e9tamine administr\u00e9e par voie veineuse pendant trois jours sur les douleurs de fibromyalgie: \u00c9tude en double-aveugle, \u00abcross-over\u00bb, versus placebo. Douleurs: Evaluation-Diagnostic-Traitement. 2005;6:151\u20139.","journal-title":"Douleurs: Evaluation-Diagnostic-Traitement"},{"key":"393_CR12","first-page":"1615","volume":"24","author":"J S\u00f6rensen","year":"1997","unstructured":"S\u00f6rensen J, Bengtsson A, Ahlner J, Henriksson K, Ekselius L, Bengtsson M. Fibromyalgia\u2013are there different mechanisms in the processing of pain? A double-blind crossover comparison of analgesic drugs. J Rhuematol. 1997;24:1615\u201321.","journal-title":"J Rhuematol"},{"key":"393_CR13","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00259-007-0589-9","volume":"34","author":"E Guedj","year":"2007","unstructured":"Guedj E, Cammilleri S, Colavolpe C, de Laforte C, Niboyet J, Mundler O. Follow-up of pain processing recovery after ketamine in hyperalgesic fibromyalgia patients using brain perfusion ECD-SPECT. Eur J Nucl Med Mol Imaging. 2007;34:2115\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"393_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0304-3959(99)00308-5","volume":"85","author":"T Graven-Nielsen","year":"2000","unstructured":"Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, S\u00f6rensen J, Johnson A, Gerdle B, Arendt-Nielsen L. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000;85:483\u201391.","journal-title":"Pain"},{"key":"393_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jpain.2005.12.010","volume":"7","author":"SP Cohen","year":"2006","unstructured":"Cohen SP, Verdolin MH, Chang AS, Kurihara C, Morlando BJ, Mao J. The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain. 2006;7:391\u20138.","journal-title":"J Pain"},{"key":"393_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1213\/ANE.0000000000004185","volume":"129","author":"V Orhurhu","year":"2019","unstructured":"Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials. Anesth Analgesia. 2019;129:241\u201354.","journal-title":"Anesth Analgesia"},{"key":"393_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","volume":"278","author":"A Bahji","year":"2021","unstructured":"Bahji A, Vazquez GH, Zarate Jr CA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542\u201355.","journal-title":"J Affect Disord"},{"key":"393_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. Elsevier. 2000;47:351\u20134.","journal-title":"Biol Psychiatry Elsevier"},{"key":"393_CR19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","volume":"175","author":"CM Canuso","year":"2018","unstructured":"Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry Am Psychiatric Assoc. 2018;175:620\u201330.","journal-title":"Am J Psychiatry Am Psychiatric Assoc"},{"key":"393_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpsychires.2020.12.038","volume":"134","author":"J Xiong","year":"2021","unstructured":"Xiong J, Lipsitz O, Chen-Li D, Rosenblat JD, Rodrigues NB, Carvalho I, Lui LM, Gill H, Narsi F, Mansur RB. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis. J Psychiatr Res. 2021;134:57\u201368.","journal-title":"J Psychiatr Res"},{"key":"393_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.psychres.2013.12.008","volume":"215","author":"M Ghasemi","year":"2014","unstructured":"Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, Afzali MH. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res. Elsevier. 2014;215:355\u201361.","journal-title":"Psychiatry Res Elsevier"},{"key":"393_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. Nature Publishing Group. 2018;23:801\u201311.","journal-title":"Mol Psychiatry Nat Publishing Group"},{"key":"393_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","volume":"264","author":"FS Correia-Melo","year":"2020","unstructured":"Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, Caliman-Fontes AT, Echegaray MV, Bandeira ID, Silva SS. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disorders. Elsevier. 2020;264:527\u201334.","journal-title":"J Affect Disorders Elsevier"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-024-00393-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T12:54:06Z","timestamp":1722257646000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-024-00393-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1186\/s42358-024-00393-9","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"It is not applicable since it is a review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JFC and EPS consent for this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"54"}}